MarketCap
Arrowhead Pharmaceuticals ARWR
$ 80.56
0.11%
Facebook
X
Telegram
Arrowhead Pharmaceuticals Total Non Current Liabilities | ARWR
Annual Total Non Current Liabilities Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 686 M | 846 M | 373 M | 135 M | 155 M | 20 M | 8.74 M | 4 M | 4.45 M | 7.51 M | 6.75 M | 4.98 M | 2.87 M | 2.39 M | 742 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 846 M | 742 K | 150 M |
Quarterly Total Non Current Liabilities Arrowhead Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 B | 1.37 B | 694 M | 694 M | 686 M | 666 M | 864 M | 864 M | 846 M | 448 M | 395 M | 389 M | 373 M | 344 M | 339 M | 373 M | 135 M | - | 112 M | 129 M | 155 M | 103 M | 155 M | 19.7 M | 20 M | 20 M | 20 M | 14.4 M | 8.74 M | 8.74 M | 8.74 M | 34.8 M | 4 M | 4 M | 4 M | 4.3 M | 4.45 M | 4.45 M | 4.45 M | 10.1 M | 7.51 M | 7.51 M | 7.51 M | 6.68 M | 6.75 M | 6.75 M | 6.75 M | 4.93 M | 4.98 M | 4.98 M | 4.98 M | 2.76 M | 2.87 M | 2.87 M | 2.87 M | 1.55 M | 2.39 M | 2.39 M | 2.39 M | 2.25 M | 742 K | 742 K | 742 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.37 B | 742 K | 190 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
5.95 M | $ 5.71 | 7.24 % | $ 700 M |  USA |
 |
Фармсинтез
LIFE
|
13.2 M | - | - | - |  Russia |
 |
AbbVie
ABBV
|
81.7 B | $ 261.51 | 1.66 % | $ 463 B | USA |
 |
AbCellera Biologics
ABCL
|
326 M | $ 11.09 | 1.84 % | $ 3.31 B |  Canada |
 |
Agenus
AGEN
|
264 M | $ 7.16 | 3.17 % | $ 213 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
497 K | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
302 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
40.3 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
24.8 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
6.69 M | $ 5.39 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
157 M | $ 33.38 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
158 M | $ 3.29 | 2.94 % | $ 194 M |  China |
 |
iTeos Therapeutics
ITOS
|
6.36 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
44 K | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 24.82 | 2.56 % | $ 3.77 B | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
1.4 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
70.5 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
MediWound Ltd.
MDWD
|
15.5 M | $ 13.84 | 5.57 % | $ 377 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
341 M | $ 1.11 | 3.76 % | $ 141 M |  Schweiz |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 27.48 | 0.04 % | $ 4.63 B | USA |
 |
AIM ImmunoTech
AIM
|
6.18 M | $ 0.22 | 0.05 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
99.5 M | $ 9.15 | 0.16 % | $ 2.18 B | USA |
 |
Axcella Health
AXLA
|
26.4 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
58.7 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
159 K | $ 7.28 | 3.12 % | $ 317 M | USA |
 |
Baudax Bio
BXRX
|
65.4 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
1.26 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
119 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | USA |
 |
Akebia Therapeutics
AKBA
|
168 M | $ 0.98 | 3.01 % | $ 252 M | USA |
 |
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
4.4 M | - | - | $ 7.29 B | USA |
 |
AC Immune SA
ACIU
|
14.7 M | $ 2.67 | 2.6 % | $ 269 M | Schweiz |
 |
Alector
ALEC
|
165 M | $ 2.22 | 3.74 % | $ 229 M | USA |